PERT

Viz.ai Wins 2024 Edison Award™ for Innovation for Second Year in a Row

Retrieved on: 
Friday, April 19, 2024
Cardiology, Biotechnology, Technology, Other Health, Health, General Health, Optical, Health Technology, Infectious Diseases, Software, Artificial Intelligence, Education, Mortality, FDA, AI, AVF, Triage, American Lung Association, Partnership, Artificial intelligence, Pulmonary embolism, Assessment, Engineering, Science, PERT, Edison Award, Edison Awards, Circulatory system, Thomas Edison, Multimedia, Marketing, Diagnosis, Viz

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that it has been named an Edison Award Winner in the 2024 Edison Awards, for the second year in a row.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that it has been named an Edison Award Winner in the 2024 Edison Awards, for the second year in a row.
  • The prestigious Edison Awards, named after the American inventor Thomas Alva Edison, honor excellence in new product and service development, marketing, design and innovation.
  • View the full release here: https://www.businesswire.com/news/home/20240419954371/en/
    “We are honored to win our second Edison Award for innovation,” said Dr. Chris Mansi, CEO and co-founder of Viz.ai.
  • Winners were announced at the Edison Awards Gala on April 18, 2024 in Fort Myers, FL.

AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE

Retrieved on: 
Thursday, April 4, 2024
Research, Medical Devices, Surgery, FDA, Cardiology, General Health, Health, Science, Oncology, Other Science, Interventional radiology, RV, Pulmonary embolism, Thrombus, Associate, Partnership, Cannula, Patient, PERT, Cancer, APEX, Assistant professor, Bleeding, Safety, UCLA, Embolism, Pharmaceutical industry

The expanded FDA indication allows for the utilization of the AlphaVac F1885 System for the treatment of PE, which broadens the applicability of the AlphaVac F1885 System in the non-surgical removal of thrombi or emboli from the venous vasculature.

Key Points: 
  • The expanded FDA indication allows for the utilization of the AlphaVac F1885 System for the treatment of PE, which broadens the applicability of the AlphaVac F1885 System in the non-surgical removal of thrombi or emboli from the venous vasculature.
  • The indication expands treatment options for patients with PE, reducing thrombus burden and improving right ventricular function.
  • “The addition of the AlphaVac System in the mechanical thrombectomy world is a critical step forward in the treatment of PE patients,” said Dr. Keeling.
  • “The 510(k) clearance of the AlphaVac System represents an important milestone towards the treatment of PE,” said Mona Ranade, MD, Assistant Professor, Interventional Radiology, at the David Geffen School of Medicine at UCLA.

English language groups host discussion on the future vitality of Quebec’s English-speaking community

Retrieved on: 
Tuesday, February 27, 2024
ELAN, FLQ, Protestantism, Poverty, Research, Employment, PERT

Montreal, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The English Language Arts Network (ELAN) and the Provincial Employment Roundtable (PERT) are hosting a discussion on the topic of economic vitality for Quebec’s English-speaking community.

Key Points: 
  • Montreal, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The English Language Arts Network (ELAN) and the Provincial Employment Roundtable (PERT) are hosting a discussion on the topic of economic vitality for Quebec’s English-speaking community.
  • In a moment characterized by decreased economic vitality for Québec’s English speakers, the discussion will be an opportunity to focus on the resilience of Quebec’s English-speaking community.
  • Nicholas Salter, Executive Director of PERT, emphasized the importance of addressing the challenges faced by English speakers in Quebec.
  • “We believe that it is important to facilitate a discussion that acknowledges the current challenges for English speakers in our province.

New Viz.ai Study Demonstrates Reduced Mortality Rates in Patients with Pulmonary Embolism

Retrieved on: 
Thursday, March 7, 2024
Software, General Health, Professional Services, Data Management, Medical Devices, Technology, Infectious Diseases, Hospitals, Artificial Intelligence, Health Technology, Data Analytics, Health, Viz, Pulmonary embolism, Multimedia, AI, AVF, Assessment, TriHealth, Mortality, American Venous Forum, PERT, Medical device

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced clinical data validating the impact of the Viz PE Solution in the management and outcomes of patients with pulmonary embolism (PE).

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced clinical data validating the impact of the Viz PE Solution in the management and outcomes of patients with pulmonary embolism (PE).
  • The data was presented during the 2024 AVF (American Venous Forum) by Jacob Shapiro, M.D., vascular surgeon at TriHealth in Cincinnati, OH.
  • View the full release here: https://www.businesswire.com/news/home/20240307999862/en/
    The real-world study, "Shorter Time to Assessment and Anticoagulation with Decreased Mortality in Patients with Pulmonary Embolism Following Implementation of Artificial Intelligence Software," evaluated the clinical impact of the Viz PE Solution on time to assessment, time to anticoagulation, and patient outcomes at TriHealth.
  • The study found that implementation of the AI-powered solution combined with PERT activation significantly improved time to assessment and time to anticoagulation with a 74% reduction in in-hospital mortality risk.

AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism

Retrieved on: 
Thursday, December 7, 2023
Medical Devices, Health, Hospitals, Clinical Trials, Cardiology, Biotechnology, UCLA, Interventional radiology, Pulmonary embolism, Associate, MMA, Safety, APEX, Assistant professor, Literature, Mortality, CDT, Patient, PERT, Acute, MD, Cancer, Trial of the century, Partnership, Travel, Deep vein thrombosis, Medical imaging, Dentistry, Surgery

APEX-AV is a clinical study aimed at evaluating the safety and efficacy of the Company’s AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System in the treatment of acute intermediate-risk pulmonary embolism (PE).

Key Points: 
  • APEX-AV is a clinical study aimed at evaluating the safety and efficacy of the Company’s AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System in the treatment of acute intermediate-risk pulmonary embolism (PE).
  • The primary efficacy endpoint of the APEX-AV Study is the reduction in RV/LV ratio between baseline and 48 hours post-procedure.
  • “The completion of the APEX-AV Study represents an important milestone in the catheter-directed therapies CDT space for the treatment of pulmonary embolism.
  • AngioDynamics initiated the APEX-AV Study in partnership with the widely respected Pulmonary Embolism Response Team (PERT) Consortium™.

First Patient in STORM-PE RCT Enrolled Evaluating Penumbra's Latest Computer Assisted Vacuum Thrombectomy - Lightning Flash™ - for Treatment of Acute Pulmonary Embolism

Retrieved on: 
Tuesday, November 28, 2023
RCT, Pulmonary embolism, NYSE, Randomized controlled trial, Risk, Lightning Flash, Patient, PERT, Embolism, Coronary thrombosis, Thrombus, RPVI, Blood, Standard of care, MBA, Bleeding, Radiology, MPH, Partnership, Massachusetts General Hospital, Physician, Lightning, Hospital, McLaren Health Care Corporation, Birth control, Nursing, Pharmaceutical industry, Umbra, penumbra and antumbra, MD

(NYSE: PEN), a global healthcare company focused on innovative therapies, announced the first patient enrolled in STORM-PE, a first-of-its-kind prospective, multi-center, randomized controlled trial evaluating anticoagulation alone vs anticoagulation plus Lightning Flash™ for the treatment of pulmonary embolism (PE).

Key Points: 
  • (NYSE: PEN), a global healthcare company focused on innovative therapies, announced the first patient enrolled in STORM-PE, a first-of-its-kind prospective, multi-center, randomized controlled trial evaluating anticoagulation alone vs anticoagulation plus Lightning Flash™ for the treatment of pulmonary embolism (PE).
  • "We have already seen the significant impact Lightning Flash can have on patients.
  • "This landmark RCT will be instrumental to advancing the standard of care for patients with pulmonary embolism."
  • Pulmonary embolism can be life-threatening with 10-30 percent of individuals dying within one month of diagnosisi.

New report shows how Québec’s French language learning ecosystem could be improved

Retrieved on: 
Wednesday, November 1, 2023
Unemployment, Workplace, PERT, Private sector, Employment, Partnership, Research, School, Government, Nursing, Management, Tourism

Montreal, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The Provincial Employment Roundtable (PERT) has released the second of two reports examining the most effective approaches in adult language learning.

Key Points: 
  • Montreal, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The Provincial Employment Roundtable (PERT) has released the second of two reports examining the most effective approaches in adult language learning.
  • The latest report, entitled "Québec and the rest: A survey of national and international approaches to adult language training," presents examples of successful adult language training programs across six international and Canadian jurisdictions, and proposes recommendations intended to help improve Québec’s adult French language training ecosystem.
  • The organisation's research has also identified French language proficiency as a barrier for English speakers navigating the labour market.
  • The report presents seven key recommendations to help improve Québec’s adult language learning infrastructure:
    Increase collaboration between the government, the community sector, and the private sector to expand the provision of adult French-language training programs.

UZ Brussel PERT and Aidoc Pave the Way as First Hospital in Europe for Expedited Treatment of Pulmonary Embolism with AI

Retrieved on: 
Thursday, October 26, 2023
Intelligence, Radiology, UZB, Physician, PERT, Acquisition, Health, Vrije Universiteit Brussel, Pulmonary embolism, PE, Hospital, CT, Embolism, AI, Patient, Diagnosis, Communication, Medical imaging, Medical device, Aidoc

LONDON, Oct. 26, 2023 /PRNewswire/ -- Aidoc today announced a pioneering collaboration with the Pulmonary Embolism Response Team (PERT) at UZ Brussel (UZB), becoming the first European hospital to use AI for cross-departmental care coordination, expediting treatment for suspected pulmonary embolism (PE) patients. Aidoc automatically flags suspected positive cases of PE and sends an automatic alert to UZ Brussel's Pulmonary Embolism Response Team (PERT), allowing for fast multidisciplinary decision-making and rapid delivery of life-saving treatment.

Key Points: 
  • Aidoc automatically flags suspected positive cases of PE and sends an automatic alert to UZ Brussel's Pulmonary Embolism Response Team (PERT), allowing for fast multidisciplinary decision-making and rapid delivery of life-saving treatment.
  • Pulmonary embolism is the third most common acute cardiovascular syndrome, resulting from a blood clot obstructing a lung artery, and can be swiftly fatal without prompt diagnosis and treatment.
  • "We are thrilled about our ongoing collaboration with Aidoc," states Marc Noppen, CEO of UZ Brussel.
  • "This innovative approach not only enhances patient care but also sets the stage for a promising future of AI-driven healthcare across Europe."

New Clinical Data Supports Viz.ai Solution for Improved Pulmonary Embolism Detection and Care Coordination

Retrieved on: 
Thursday, September 21, 2023
Nursing, Cardiology, Technology, Health, Health Technology, Medical Devices, Apps, Applications, Software, Artificial Intelligence, Hospitals, Surgery, PE, Use, Workflow, Temple University, Pulmonary embolism, VPS Healthcare, Research, TriHealth, PERT, Viz, Triage, Patient, Treatment, Algorithm, Artificial intelligence, AI, Detection, CTPA, Dentistry, Medical device, Medicine

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in pulmonary embolism (PE) detection.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in pulmonary embolism (PE) detection.
  • Two studies have demonstrated the real-world clinical efficacy of Viz.ai's PE Module to quickly and accurately identify PE and associated right heart strain, accelerate care coordination, and improve healthcare workflow efficiency.
  • Pulmonary embolism is a severe medical condition, which affects around 900,000 people in the U.S. every year, and often challenging to diagnose and treat due to overlapping symptoms with other diseases.
  • The study found that, across 100 retrospectively-collected chest CTPA images, Viz PE demonstrated a sensitivity of 91.1% and specificity of 100.0%.

Aidoc's AI Solution for Pulmonary Embolism Clinically Proven to Reduce Hospital Stay Duration and Improves Patient Access to Treatment

Retrieved on: 
Friday, September 22, 2023
Learning, Medicine, CT, University of Texas Medical Branch, University, Workflow, Peer review, Pulmonary embolism, EMR, University of Chicago, Intelligence, Research, PERT, Chicago Department of Public Health, Embolism, Radiology, UTMB, Triage, Patient, Jamaica Hospital Medical Center, PES, Artificial intelligence, AI, ICU, Health, Candace Pert, Nursing, Medical imaging, Medical device, Aidoc

AUSTIN, Texas, Sept. 22, 2023 /PRNewswire/ -- Groundbreaking research in the advancement of AI-driven pulmonary embolism (PE) care was unveiled yesterday evening during the 9th Annual Pulmonary Embolism Symposium. Research from three leading institutions utilizing Aidoc's PE AI solution demonstrated immense clinical value in reducing mean hospital length of stay, improving patient access, and correctly alerting care teams of suspected PEs with potential for advanced interventions.

Key Points: 
  • Research from three leading institutions utilizing Aidoc's PE AI solution demonstrated immense clinical value in reducing mean hospital length of stay, improving patient access, and correctly alerting care teams of suspected PEs with potential for advanced interventions.
  • The three studies highlighted the care advantages of utilizing Aidoc in the management of acute pulmonary embolisms, including numerous patient outcome benefits.
  • Key findings from the studies presented include:
    "Proving the robustness of any AI solution hinges on the application of scientific rigor and the scrutiny of peer review.
  • These studies illustrate the ongoing evolution of Aidoc's AI-powered PE solution from an algorithm to enterprise-wide platform used by Pulmonary Embolism Response Teams (PERTs) across entire health systems.